Jose Montero-Cabezas

Dr. Jose Montero-Cabezas


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2024 in EP Europace
Verified
Journal Article
Open access
PDF file
RLRadoslaw K Lenarczyk
Radoslaw K Lenarczyk
KZKatja Zeppenfeld
Katja Zeppenfeld
JTJacob Tfelt-Hansen
Jacob Tfelt-Hansen
FHFrank R Heinzel
Frank R Heinzel
TDThomas Deneke
Thomas Deneke
JAJacob Atié
Jacob Atié
Electrical storm (ES) is a state of electrical instability, manifesting as recurrent ventricular arrhythmias (VAs) over a short period of time (three or more episodes of sustained VA within 24 h, separated by at least 5 min, requiring termination by an intervention). The clinical presentation can vary, but ES is usually a cardiac emergency. Electrical storm mainly affects patients with structural or primary electrical heart disease, often with an implantable cardioverter-defibrillator (ICD). Management of ES requires a multi-faceted approach and the involvement of multi-disciplinary teams, but despite advanced treatment and often invasive procedures, it is associated with high morbidity and mortality. With an ageing population, longer survival of heart failure patients, and an increasing number of patients with ICD, the incidence of ES is expected to increase. This European Heart Rhythm Association clinical consensus statement focuses on pathophysiology, clinical presentation, diagnostic evaluation, and acute and long-term management of patients presenting with ES or clustered VA.

18 August 2022 in European Journal of Internal Medicine
Verified
Journal Article
Closed access
Leonardo De LucaLeonardo De Luca
Leonardo De Luca
ASAngelo Silverio
Angelo Silverio
MVMonica Verdoia
Monica Verdoia
ZSZbigniew Siudak
Zbigniew Siudak
TTTomasz Tokarek
Tomasz Tokarek
GGGennaro Galasso
Gennaro Galasso

10 August 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
EPElma Peters
Elma Peters
SBSanne Ten Berg
Sanne Ten Berg
MBMargriet Bogerd
Margriet Bogerd
MTMarijke J. C. Timmermans
Marijke J. C. Timmermans
AKAdriaan Kraaijeveld
Adriaan Kraaijeveld
ORon behalf of the Participating Centers of the PCI Registration Committee of the Netherlands Heart Registration
on behalf of the Participating Centers of the PCI Registration Committee of the Netherlands Heart Registration
Cardiogenic shock (CS) complicating acute myocardial infarction (AMI) is associated with high morbidity and mortality. Our study aimed to gain insights into patient characteristics, outcomes and treatment strategies in CS patients. Patients with CS who underwent percutaneous coronary intervention (PCI) between 2017 and 2021 were identified in a nationwide registry. Data on medical history, laboratory values, angiographic features and outcomes were retrospectively assessed. A total of 2328 patients with a mean age of 66 years and of whom 73% were male, were included. Mortality at 30 days was 39% for the entire cohort. Non-survivors presented with a lower mean blood pressure and increased heart rate, blood lactate and blood glucose levels (p-value for all <0.001). Also, an increased prevalence of diabetes, multivessel coronary artery disease and a prior coronary event were found. Of all patients, 24% received mechanical circulatory support, of which the majority was via intra-aortic balloon pumps (IABPs). Furthermore, 79% of patients were treated with at least one vasoactive agent, and multivessel PCI was performed in 28%. In conclusion, a large set of hemodynamic, biochemical and patient-related characteristics was identified to be associated with mortality. Interestingly, multivessel PCI and IABPs were frequently applied despite a lack of evidence.

2 October 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
AKAisha Khalid
Aisha Khalid
HMHans Mautong
Hans Mautong
KAKayode Ahmed
Kayode Ahmed
ZAZaina Aloul
Zaina Aloul
JMJose Montero-Cabezas
Jose Montero-Cabezas
SMSilvana Marasco
Silvana Marasco
Introduction: Trans-radial access for coronary angiography and percutaneous coronary intervention (PCI) has gained popularity due to its advantages over the traditional transfemoral approach. However, radial artery occlusion (RAO) remains a common complication following trans-radial procedures. This study aimed to investigate the incidence of early and late RAO along with their risk factors. Methods: Six databases, Medline (Ovid), National Library of Medicine (MeSH), Cochrane Database of Systematic Reviews (Wiley), Embase, Scopus, and Global Index Medicus, were searched. The systematic review and meta-analysis followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Data were extracted and analyzed. Using a random-effect model, the primary endpoint was the overall incidence of RAO after invasive coronary procedures. Subgroup analysis and meta-regression were also performed to identify possible predictors of RAO. Results: A total of 41 studies with 30,020 patients were included. The overall incidence of RAO was 13% (95% CI = 0.09–0.16). The incidence of early RAO (within 24 h) was 14% (95% CI = 0.10–0.18) in 26 studies, while the incidence of late RAO (after 24 h) was 10% (95% CI = 0.04–0.16) in 22 studies. The average incidence rates of early RAO in studies with catheter sizes of 6 Fr were 9.8%, 9.4%, and 8.8%. The overall effect size of female gender as a predictor was 0.22 with a 95% CI of 0.00–0.44. Age was a potential predictor of early RAO (B = 0.000357; 95% CI = −0.015–0.0027, p: 0.006). Conclusions: This meta-analysis provides essential information on the incidence of early (14%) and late (10%) RAO following angiographic procedures. Additionally, our findings suggest that female sex and age are possible predictors of RAO. A larger catheter, especially (6 Fr) and hemostatic compression time <90 min post-procedure, substantially reduced the incidence of RAO. The use of oral anticoagulation and the appropriate dosage of low-molecular-weight heparin (LMWH) does reduce RAO, but a comparison between them showed no statistical significance.

1 June 2019 in Canadian Journal of Cardiology
Verified
Journal Article
Closed access
JMJose Montero-Cabezas
Jose Montero-Cabezas
RMR.W. van der Meer
R.W. van der Meer
FKFrank van der Kley
Frank van der Kley
CKCarlos V. Elzo Kraemer
Carlos V. Elzo Kraemer
JMJorge E. López Matta
Jorge E. López Matta
AWA. de Weger
A. de Weger

28 March 2016 in Annals of Noninvasive Electrocardiology
Verified
Journal Article
Closed access
PDF file
JMJose Montero-Cabezas
Jose Montero-Cabezas
IKIoannis Karalis
Ioannis Karalis
MSMartin J. Schalij
Martin J. Schalij